期刊
MOLECULAR NEUROBIOLOGY
卷 52, 期 1, 页码 375-385出版社
HUMANA PRESS INC
DOI: 10.1007/s12035-014-8866-7
关键词
Stroke; Metformin; Preconditioning; NF-kappa B; Inflammation
资金
- National Natural Science Foundation of China [81171209, 81371406, 81000544]
- Shandong Provincial Natural Science Foundation [ZR2011HZ001, ZR2010HQ004]
- Medicine and Health Science Technology Development Project of Shandong Province [2011WSA02018, 2011WSA02020]
- Innovation Project for Postgraduates of Jiangsu Province [CXLX13_561]
Accumulating evidence suggests that chronic metformin preconditioning offers potent neuroprotective effects against ischemic stroke. However, the underlying mechanisms remain largely unknown. In this study, we tested the hypothesis that chronic preconditioning with metformin conferred neuroprotection via suppression of nuclear factor kappa B (NF-kappa B)-mediated inflammatory pathway. Male Sprague-Dawley rats were treated with vehicle or metformin (50 mg/kg daily, i.p.) for 3 weeks and were subjected to permanent middle cerebral artery occlusion (pMCAO). At 24 h (acute phase) and 96 h (subacute phase) after pMCAO, infarct volume and neurological deficits were evaluated. Meanwhile, the activity of NF-kappa B and the levels of its downstream pro-inflammatory cytokines were detected at 24 h after pMCAO. Our results showed that chronic metformin preconditioning significantly reduced infarct volume and improved neurological deficits at 24 and 96 h after pMCAO. It also suppressed brain NF-kappa B activity, which was accompanied by a reduction of pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-6, and induced nitric oxide synthase in the peri-infarct regions at 24 h after pMCAO. Moreover, the microgliosis and astrocytosis induced by pMCAO were also ameliorated by chronic metformin preconditioning. Collectively, the present study provides the first evidence that suppression of NF-kappa B-mediated inflammatory pathway may represent one potential mechanism underlying the neuroprotection of chronic metformin preconditioning. In addition, our findings suggest that metformin, a first-line drug for glycemic control, has a practical clinical use for stroke prevention and treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据